Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

Combining immune checkpoint therapy (ICT) and targeted therapy holds great promises for broad and long-lasting anti-cancer therapies. However, combining ICT with anti-PI3K inhibitors have been challenging because the multifaceted effects of PI3K on both cancer cells and immune cells within the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Zhi, Xu, Zihan, Zhang, Liuzhen, Zou, Yongkang, Li, Jinping, Yan, Wenyu, Li, Cheng, Liu, Ningshu, Wu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748754/
https://www.ncbi.nlm.nih.gov/pubmed/35013322
http://dx.doi.org/10.1038/s41467-021-27833-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748754/
https://www.ncbi.nlm.nih.gov/pubmed/35013322
http://dx.doi.org/10.1038/s41467-021-27833-0

Ejemplares similares